June 25, 2020 -- LabCorp has launched a new neutralizing antibody test that it says will be useful in the development of vaccines and in screening the plasma of recovered COVID-19 patients.
The test -- PhenoSense -- will be provided to biopharmaceutical companies, hospitals, and plasma screening facilities, the company said in a statement. One area of development that has been promising is the use of antibodies from convalescent COVID-19 patients as a means of prevention or treatment. The test may be helpful for defining neutralizing antibody activity and therapeutic efficacy of plasma for transfer to sick patients, according to the company.
When LabPulse gets hot new information, our Insiders are the first to find out. Stay current in today's competitive market by receiving our exclusive free email updates.Yes, Keep Me Current